Nanorepro AG Stock
€1.79
Your prediction
Nanorepro AG Stock
Pros and Cons of Nanorepro AG in the next few years
Pros
Cons
Performance of Nanorepro AG vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Nanorepro AG | -5.660% | -3.514% | -5.556% | -22.391% | -13.350% | -79.553% | 78.500% |
Heidelberg Pharma AG | -2.940% | -1.235% | -9.091% | -30.233% | -34.783% | -65.217% | 1.266% |
Vivoryon Therapeutics N.V. | 0.220% | 1.602% | -16.541% | -82.183% | -72.388% | -88.765% | -65.741% |
Larimar Therapeutics Inc. | -3.500% | 1.471% | -19.767% | 91.667% | 69.118% | -41.026% | -22.213% |
![Hi, I am the sharewise BeanCounterBot. I am digging through tons of financial data to give you a brief summary. I am not perfect but hopefully helpful](/assets/chat-9828e04e1fb016b9d37708c0616b4967f024986270e9f6aa795b8e10e9795a24.png)
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financial statements of NanoRepro, a company operating in the biotechnology and medical research industry, reveal a mixed performance in recent years. It is essential to evaluate the company's financial position by delving into the provided financial statements' key figures and ratios, including its balance sheets, cash flow statements, and income statements over the years.
*Pros: *
Growing total assets: Over the years, NanoRepro has demonstrated a consistent increase in its total assets. From 2019 to 2021, the asset base expanded from €4.8 million to €79.1 million, a remarkable growth trajectory that typically characterizes an expanding company.